AbbVie (ABBV) return on invested capital (ROIC)

Return on invested capital · fiscal 2025
22.1%

AbbVie (ABBV) earned a return on invested capital of 22.1% in fiscal 2025 (the year ended December 31, 2025). That is 3.8 percentage points higher than the 18.3% of fiscal 2024. Figures as of 18 Nov 2026, 01:08 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on invested capital, fiscal 2025
22.1%
Change on fiscal 2024
+3.8 pts
Highest on record
23.2%fiscal 2022
Lowest on record
18.3%fiscal 2024
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

AbbVie return on invested capital (ROIC), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 23.2% in fiscal 2022 and the lowest 18.3% in fiscal 2024. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 18.5%.

History · 4 fiscal years

Return on invested capital by fiscal year

AbbVie return on invested capital (ROIC), year by year

AbbVie (ABBV) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
202522.1% 3.8 pts up
202418.3% 0.2 pts down
202318.5% 4.7 pts down
202223.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

Return on invested capital at health care companies of similar size

Return on invested capital of AbbVie and comparable companies
CompanyReturn on invested capitalFiscal year
Eli Lilly LLY38.6%2025
Johnson & Johnson JNJ19.3%2025
AbbVie ABBV22.1%2025
Merck & Co MRK21.9%2025
UnitedHealth Group UNH11.4%2025
Novartis NVS21.5%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ABBV

AbbVie, figure by figure

AbbVie (ABBV) overview: price, valuation and scorecardAll health care companies by market value

AbbVie return on invested capital (ROIC): questions and answers

What is AbbVie's return on invested capital?

AbbVie (ABBV) earned a return on invested capital of 22.1% in fiscal 2025 (the year ended December 31, 2025). That is 3.8 percentage points higher than the 18.3% of fiscal 2024.

Is AbbVie's return on invested capital high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 18.5%.

What are the highest and lowest return on invested capital figures on record for AbbVie?

Across the 4 fiscal years on record (2022–2025), the highest was 23.2% in fiscal 2022 and the lowest 18.3% in fiscal 2024.

How is AbbVie's return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “AbbVie (ABBV) return on invested capital (ROIC)”, data as of 18 November 2026. https://funkfolio.com/stock/ABBV/roic

Underlying data: the company's filings with the SEC and Yahoo Finance.